A late-stage study of two rheumatoid arthritis drugs from Bristol Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) showed a significant drop in deaths among hospitalized COVID patients, a U.S. health agency said on Thursday.
https://www.pharmalive.com/wp-content/uploads/2021/12/Bristol-Myers-is-sued-for-refusing-COVID-19-vaccine-religious-exemptions-Reuters-12-1-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-02 16:48:082022-06-03 03:01:29Bristol Myers, J&J drugs reduce COVID death rates in NIH study
